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Abstract Pseudogenes are commonly encountered during in-
vestigation of the genomes of a wide range of life forms. This
review concentrates on vertebrate, and in particular mammalian,
pseudogenes and describes their origin and subsequent evolution.
Consideration is also given to pseudogenes that are transcribed
and to the unusual group of genes that exist at the interface
between functional genes and non-functional pseudogenes. As the
sequences of different genomes are characterised, the recognition
and interpretation of pseudogene sequences will become more
important and have a greater impact in the field of molecular
genetics.
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1. What is a pseudogene and whence do they originate?
A pseudogene is a sequence which is present in the genome
of a given population and typically is characterised by close
similarities to one or more paralogous genes, yet is non-func-
tional. This lack of function is a result of either failure of
transcription or translation, or production of a protein that
does not have the same functional repertoire as the protein
encoded by the normal paralog gene. A fundamental feature
of pseudogenes is that their nucleotide sequences di¡er from
those of the paralogous functional genes at crucial points.
Vanin [1] stressed that the term pseudogene is only applicable
to sequences that are related to another sequence but are
defective. Pseudogenes have been denoted in several ways in-
cluding the pre¢xed Greek symbol i, for example iPGK-1, or
by a capital ‘P’ su⁄x, for example CYP21P.
The term ‘pseudogene’ originally arose from investigation
of the genome of Xenopus laevis [2]. Subsequently, pseudo-
genes have been identi¢ed in a diverse range of life forms
including bacteria, plants, insects and vertebrates [3^5].
A schematic overview of the issues covered in this review is
presented in Fig. 1. Pseudogenes are a consequence of gene
duplication which can occur in two fundamentally di¡erent
ways: ¢rstly, by retrotransposition and, secondly, via the du-
plication of genomic DNA.
2. Pseudogenes arising by retrotransposition
Pseudogenes arising by retrotransposition are known as ei-
ther processed pseudogenes or retro-pseudogenes. They are
typically characterised by an absence of both 5P-promoter se-
quence and introns, the presence of £anking direct repeats and
a 3P-polyadenylation tract [1,6]. Processed pseudogenes are
retrotransposons, that in common with other retrotranspo-
sons, have been inserted into the genome as double-stranded
sequence generated from single-stranded RNA [1,6,7]. Pro-
cessed pseudogenes are probably generated by RNA polymer-
ase II rather than the RNA polymerase III transcription re-
sponsible for other retrotransposons such as either Alu or
LINE repeats [8].
Retrotransposition of any sequence is potentially threaten-
ing to normal genome function, yet the mechanisms that con-
trol this process remain poorly understood [9^11]. Processed
pseudogenes have been generated in-vitro at a low frequency
in human HeLa cells via mRNA from a reporter gene [8]. The
resultant pseudogenes had features consistent with the pro-
cessed pseudogenes observed in mammalian genomes. This
study demonstrated that human cells possess an endogenous
reverse transcription activity that is not restricted to tran-
scripts of transposable elements [8].
The majority of retrotransposed genes are inactivated to
processed pseudogenes, but in a few instances the retrotrans-
poson is maintained as a functional, intronless gene. Two
intronless retrotransposons, iPGK-1 and PGK-2, were de-
rived from the functional, intron-containing human PGK-1
gene. iPGK-1 is a typical processed pseudogene, but PGK-2
generates transcripts that are translated into a protein with a
high homology to that encoded by PGK-1 [12,13]. Similarly,
there are three closely related murine Amd genes. Amd-1 in-
cludes introns and codes for a 334 amino acid protein whereas
Amd-2 is an intronless retrotransposon that codes for a func-
tional protein with only two amino acid di¡erences from
Amd-1 [14]. Amd-3 is also an intronless retrotransposon with
a high nucleotide identity to Amd-2, but Amd-3 is unable to
encode a functional protein and is a processed pseudogene
[14].
3. Pseudogenes arising by duplication of genomic DNA
Duplication of DNA segments has been essential in the
development of complex genomes and explains the generation
of gene families from a single ancestral gene [15,16]. The
composition of any genome is not static and must inevitably
change with time. The mechanisms by which duplicated genes
either take on new adaptive functions, are maintained as they
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were at the time of duplication or become neutralised to pseu-
dogenes remain an area of intense debate [17^21]. In simple
terms, pseudogenes represent genes that were not maintained
as functional elements either because they conferred a selec-
tion disadvantage or because they did not give a selection
advantage to the organism in evolutionary terms. This inter-
pretation is made with the caveat that the duplicated sequence
was functional immediately after duplication. If duplication
was incomplete then the new sequence would be a pseudogene
from the outset.
The 5P-end of the BRCA1 gene lies within a 30 kb region of
chromosome 17 that has undergone tandem duplication. This
has resulted in a iBRCA1 gene paralogous to the 5P-end of
BRCA1, but which only includes exons 1A, 1B and 2 [22]. It is
extremely unlikely that this iBRCA1 was ever functional at
the protein level. The human iPS, iSORD and iMTX genes
lack their respective exon 1 sequences which include the me-
thionine start codons and so presumably these pseudogenes
were never functional [23^25]. Alternatively, exon 1 deletions
could have occurred some time after duplication. By contrast,
some genes were almost certainly functional before being si-
lenced into pseudogenes. For example, Hox genes have fun-
damental roles in patterning during development and are
highly conserved between di¡erent species. However, during
evolution of the pu¡er ¢sh genome two Hox genes which are
ubiquitously expressed in other species, have been silenced to
pseudogenes [26,27].
4. Numbers of pseudogenes
Pseudogenes are common, but it is not possible to quantify
the number of pseudogenes within a particular genome until it
has been completely sequenced. Even then, it may be di⁄cult
to di¡erentiate between some pseudogenes and functional
genes for reasons that will be discussed later. Initial interpre-
tation of the sequence data from human chromosome 22 in-
dicated that 19% of the coding sequences were pseudogenes
[28]. Of these, 82% were processed pseudogenes.
Vertebrate genomes include a large number of genes with
paralogous pseudogenes yet it is also probable that many
genes do not have pseudogenes. The number of pseudogenes
for any paralogous gene can vary tremendously from a single
one to multiple non-functional copies. Ribosomal RNA genes
can have hundreds of paralogous pseudogenes [29]. Highly
polymorphic loci frequently include large numbers of pseudo-
genes and this is particularly well illustrated with immuno-
globulin loci. For example, the murine immunoglobulin kap-
pa light chain gene locus includes over 140 VU genes and
paralogous pseudogenes of which at least 47 are pseudogenes
[30,31]. Interpretation of such loci can be di⁄cult and will be
returned to in a later section.
Housekeeping genes may also have several pseudogenes.
For example, in the rat there is one functional Geranylgera-
nyltransferase I gene, but at least 13 similar paralogous pseu-
dogenes that have arisen by retrotransposition of a mis-spliced
transcript [32].
In the human genome there are two loci, at chromosomes
15q11.2 and 16p11.2, that each includes a cassette of pseudo-
genes, where the cassette can be expanded to several copies at
the same locus. These cassette expansions are believed to be a
normal euchromatic variant and are of unknown signi¢cance
[33^35].
5. Location of pseudogenes
Potentially, pseudogenes can be located anywhere within a
genome although they are more likely to persist over time in
loci where they do not cause a deleterious e¡ect. The mecha-
nisms of retrotransposition mean that retrotransposons, in-
cluding processed pseudogenes, are often clustered together
at common loci, although a single retrotransposed element
can occur in isolation [36,37]. Pseudogenes generated by du-
plication of genomic DNA are more likely than processed
pseudogenes to be adjacent to their paralogous functional
gene, but can be inserted into a di¡erent chromosome. For
example, the majority of the human immunoglobulin VV light
chain pseudogenes are clustered with their paralogous func-
tional genes on chromosome 22q11.2. Two further ‘orphan’
human VV light chain pseudogenes are present at chromo-
some 8q11.2 and are believed to have arisen by a single du-
plication and translocation event that occurred before the
divergence of humans and gorillas [38]. By contrast, human
olfactory receptor pseudogenes have been distributed to most
of the human chromosomes by duplication of genomic DNA
[39,40].
Pseudogenes can also be identi¢ed both within genes or in
their control elements. The promoter regions of the human
Type 1 angiotensin II receptor gene, of each of the amylase
genes and of the prostate-speci¢c transglutaminase gene all
include a pseudogene unrelated to the functional gene
[15,41,42]. Intronic pseudogenes are present in the human
ATP7 and p53 genes [43,44]. The insertion of pseudogenes
within exons will almost inevitably alter gene function that
will either be selected against or less likely, will generate a
gene with a novel function.
Pseudogenes arising from human mitochondrial DNA can
be inserted within nuclear DNA adding a further level of
complexity to the analysis of mitochondrial disease [45,46].
6. The fate of pseudogenes
The locus of insertion of a pseudogene is fundamental to its
subsequent evolution. Insertion of some pseudogenes will
have a deleterious e¡ect on normal function of other genes
and will be rapidly selected against and lost. Many other
pseudogenes persist and evolve with time.
Established pseudogenes would be expected to undergo ge-
netic drift as there are no apparent selection pressures to
prevent either random mutations or deletions and insertions
[47]. This is supported by the observation that processed
pseudogenes mostly evolve more rapidly than their func-
tional paralogs [48]. Analysis of 109 processed pseudogenes
demonstrated that nucleotide deletions or insertions occurred
once for every 40 or 100 nucleotide substitutions, respectively
[49].
Inserted retrotransposons, such as either Alu or LINE se-
quences, may persist in pseudogenes whereas they would be
expected to have a signi¢cantly deleterious e¡ect on function
when inserted into the paralogous functional gene. Alu se-
quences are present in some functional genes and their mature
mRNAs, but Alu sequences are rarely identi¢ed in protein-
coding regions [50,51]. Accordingly, the recognition of an Alu
sequence within an apparently protein coding region can al-
low rapid identi¢cation of a pseudogene [42,52,53]. The pres-
ence of intronic Alu sequences in one but not another paral-
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ogous gene can also be a convenient pointer to which gene is a
pseudogene [25].
Established pseudogenes can potentially be copied to gen-
erate further pseudogenes. A processed iPCNA has later been
partially duplicated to give a second pseudogene at the same
locus [54]. The human amylase gene family (AMY) originated
from a single ancestral gene that had a Q-actin processed pseu-
dogene inserted into its promoter. Subsequent gene duplica-
tion and evolution resulted in an uninterrupted Q-actin pseu-
dogene in AMY2B, a partially deleted Q-actin pseudogene that
includes a long terminal repeat (LTR) in AMY2A, and parti-
ally deleted Q-actin pseudogenes that include two LTRs in
AMY1A, AMY1B and AMY1C [12].
The evolution of many pseudogenes follows the patterns
expected for non-functional sequences. However, it is appar-
ent that that factors other than evolutionary time can have a
signi¢cant in£uence on pseudogene evolution [49]. Nucleotide
changes are not always random and, for example, several
disease-associated nucleotide substitutions in human PMM2
are also present in the paralogous pseudogene [48,55]. Some
pseudogenes exhibit accelerated genetic drift for reasons
which are not readily apparent [56]. Other pseudogenes are
remarkably similar to their paralogous functional gene. The
murine processed iTsg101 has 98% nucleotide identity to
Tsg101 cDNA, but the pseudogene includes a frameshift mu-
tation and a premature stop codon which would generate a
very di¡erent protein lacking some of the key functional do-
mains of Tsg101 [19]. The transcribed intronless human
iPTEN has 98.6% homology to functional PTEN cDNA,
but 18 of its 19 nucleotide di¡erences are located in the pro-
tein coding region and iPTEN lacks a translation initiation
methionine codon [57]. The high nucleotide similarity may
simply represent recent pseudogene formation. However, ex-
amples have been identi¢ed where pseudogene sequences are
maintained by functional demands.
The sequence similarity between a functional gene and its
paralogous pseudogene(s) can provide a good matrix for ge-
nomic rearrangement and gene conversion, particularly where
the two genes are situated close to each other. This process
can have a key functional role and is best understood through
study of the chicken immunoglobulin genes. Both chickens
and mammals need to generate diversity in the variable do-
mains of the immunoglobulin heavy (VH) and light (VL)
chains during B-cell development, but achieve this diversity
in very di¡erent ways. Mammals rely on a number of di¡erent
functional immunoglobulin VH and VL genes whereas chick-
ens have only a single functional copy each of a VH and VL
gene. Instead, chickens generate diversity by somatic cell gene
conversion of the functional VH and VL genes by a number of
di¡erent paralogous VH and VL pseudogenes [58].
In mammals, gene conversion events involving pseudogenes
are rarer and as yet have not been identi¢ed to play such
fundamental roles as in chickens. Nucleotide point mutations
with signi¢cant e¡ects on protein function have been gener-
Fig. 1. A schematic summary, to be interpreted in conjunction with the text, of the principal issues covered in this review of vertebrate pseudo-
genes. The width of the arrows gives a rough guide to the relative importance of the di¡erent pathways at each level. A: Origin of pseudo-
genes. The majority of vertebrate pseudogenes are probably derived from functional genes. B: Mechanism of pseudogene formation. The major-
ity of vertebrate pseudogenes are a result of retrotransposition of transcripts derived from genes that encode functional proteins. C: Pseudogene
location. Pseudogenes persist in parts of the genome where they do not have a deleterious e¡ect on ¢tness of the organism. D: Pseudogene
fate. Most pseudogenes undergo genetic drift and are never transcribed. By contrast, in some instances there appears to selectional pressures
that prevent major changes to the pseudogene sequence. A few pseudogenes are involved in gene conversion and a few can be transcribed. Ac-
cordingly, not all pseudogenes are unequivocally functionless.
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ated by gene conversion of the murine lactate dehydrogenase
gene by its pseudogene [59]. In an unusual example, a human
pseudogene can potentially become functional again. The hu-
man K-globin cluster of genes on chromosome 16 has arisen
by gene duplication and divergence. This cluster includes j2,
which is brie£y expressed in the embryonic yolk sac, and its
paralogous pseudogene ij1 [60]. j2 and ij1 are almost iden-
tical at the nucleotide level, but ij1 has a non-functional
promoter. In some individuals, gene conversion of ij1 by
j2 has resulted in restoration of a functional promoter and
the generation of j1 from ij1 [61]. j2-j1 alleles are common
in a number of populations, but despite being potentially
functional, it is not clear if j1 is then transcribed [61]. The
evolution of seminal ribonuclease genes and their paralogous
pseudogenes has been investigated in mammals and there is
evidence which supports conversion of a seminal ribonuclease
pseudogene to a functional gene in recent evolutionary history
[62].
Gene conversion involving pseudogenes can have a delete-
rious e¡ect on the ¢tness of the organism and is the funda-
mental event in the pathogenesis of some diseases where part
of a gene is replaced by its pseudogene. These include muco-
polysaccharidosis type II, congenital adrenal hyperplasia and
Gaucher disease with the respective genes involved being IDS,
CYP21 and GBA [63^68].
Other gene conversion events involving pseudogenes are of
less apparent signi¢cance. For example, the long-standing bo-
vine L-lactoglobulin pseudogene appears to have had its 3P-end
recently converted by the functional L-lactoglobulin gene [69].
The 3P-end of the murine H2a pseudogene is the target of
frequent gene conversion by functional H2a genes [70].
The contrasts between the evolution of genes and their pa-
ralogous pseudogenes can be quite dramatic, as illustrated
above by the comparison of mammalian and chicken immu-
noglobulin genes. Many other examples are recognised. Nu-
cleotide analysis of gene families including their pseudogene
paralogs can thus provide a powerful tool for phylogenetic
studies that investigate genome evolution between di¡erent
species and between di¡erent populations within individual
species [62,71^76].
7. Some pseudogenes can be transcribed
Consideration of how pseudogenes are formed suggests that
most are unlikely to be transcribed, but pseudogene tran-
scripts can nevertheless be identi¢ed [13,77,78]. The functional
relevance of pseudogene transcripts remains unclear.
Processed pseudogenes cannot include all the transcription-
al control elements present in their paralogous functional
gene. Accordingly, they must use other transcriptional ele-
ments in the same way that functional retrotransposed genes
do. The intronless, functional PGK-2 originated as a retro-
transposon of PGK-1, yet it is still transcribed despite the
GC-rich promoter of PGK-1 being replaced by an AT repeat
in PGK-2 [13]. A similar situation occurs with the functional
murine retrotransposon Amd-2 that has to employ a very
di¡erent and much less e⁄cient promoter than the one used
by the intron-containing Amd-1 gene from which it originated
[14]. Alternatively, pseudogene transcription can be driven by
a nearby promoter present in unrelated sequence. For exam-
ple, the promoter of human CYP21A1 drives transcription of
an adjacent, unrelated pseudogene [79]. A human topoisomer-
ase I pseudogene and a murine iFgfr-3 are transcribed in an
antisense direction re£ecting the insertion of these pseudo-
genes adjacent to a functional, but unrelated promoter [80,81].
Pseudogenes derived from genomic DNA duplication po-
tentially include the transcriptional control elements. These
usually represent a relatively small proportion of the whole
gene compared to its protein coding regions. Accordingly, it
can be envisaged that a pseudogene might be non-functional
due to nucleotide mutations in the protein-coding parts of its
sequence, whereas the control elements are maintained and
pseudogene transcripts are produced [17]. Transcriptional
control element nucleotide changes can be identi¢ed in pseu-
dogenes of this class and the loss of methylated CpG residues
may contribute to gene silencing [82,83]. Even where tran-
scriptional control elements appear potentially functional, nu-
clear architecture and intranuclear tra⁄cking of transcription
factors may exert a powerful in£uence on transcription [84].
Pseudogene transcripts can be more prevalent than the
functional paralogous transcripts. PTEN is a tumour suppres-
sor gene implicated in cancer development as a result of either
somatic or germline mutations. In the analysis of PTEN and
iPTEN transcripts in a variety of tissues, iPTEN was the
predominant transcript in liver and glioblastoma cell lines, but
represented a minor species in spleen and kidney [77]. The
spatial expression of pseudogene transcripts can di¡er from
that of the paralogous gene transcripts. Human 5-HT7 recep-
tor pseudogene transcripts can be identi¢ed in tissues such as
kidney and liver whereas the functional 5-HT7 receptor tran-
scripts cannot be detected [78]. Pseudogene transcripts can
even be alternatively spliced [53,78,85].
Recognition of the extensive sequence identity between
some pseudogenes and their paralogous functional genes is
essential to meaningful mutational analysis by RT-PCR. For
example, RT-PCR assay design may have to distinguish be-
tween a functional transcript, an almost identical pseudogene
transcript and the genomic processed pseudogene present in
DNA contaminating the RNA sample [86^90]. Detection of
human cytokeratin 19 (CK19) transcripts has been proposed
as a sensitive marker of metastatic epithelial cancer cells in
tissues that normally do not express CK19, such as blood,
lymph nodes and bone marrow. However, the oligonucleotide
primers initially used for this assay allowed detection of a
novel iCK19 which casts signi¢cant doubts on the validity
of previously published results [91].
8. The pseudogene twilight zone
A small subset of apparent pseudogenes appear, on current
evidence, to be non-functional although this may have to be
re-evaluated in the future. The human laminin receptor
(LAMR) gene family includes a number of processed pseudo-
genes. One of these, LAMRL5, has 97.9% nucleotide identity
with the functional LAMR1, includes upstream TATA and
CAAT boxes and codes for a protein with 97% amino acid
homology to LAMR1. Currently there are no data to suggest
that LAMRL5 is ever transcribed [91]. Similarly, a human
processed iCK2K includes transcriptional control elements
and has a complete open reading frame, but evidence of tran-
scription has not been established [92].
Interpretation of highly polymorphic loci can be extremely
di⁄cult. The murine immunoglobulin VU gene locus includes
over 140 genes and paralogous pseudogenes [30,31]. Eighteen
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of these sequences are unequivocally pseudogenes and have
been designated ‘relics’ due to multiple nucleotide substitu-
tions, deletions and insertions that would prevent encoding
a functional kappa light chain. Equally, there are other se-
quences that ful¢ll the strict criteria for a functional VU gene.
Between these two extremes there are a group of sequences
that are less easy to interpret. These include sequences that
have single base pair di¡erences in their sequence compared to
the consensus VU sequences of key functional domains. Anal-
ysis of VU cDNA populations must be made with caution. As
illustrated above, the presence or absence of a speci¢c cDNA
does not necessarily con¢rm or refute whether a gene is func-
tional or not. Furthermore, the VU cDNA mutations that are
a feature of this highly polymorphic group of genes can make
it di⁄cult to identify the originating gene.
In these and other examples it cannot be stated with cer-
tainty that a gene is unequivocally either a pseudogene or a
gene. It is possible that analysis has not been performed in the
appropriate temporo-spatial conditions to detect expression.
Equally, a greater understanding about the biology of certain
genes and their paralogous pseudogenes may be required be-
fore interpretation can be made with more certainty.
9. Conclusions
Pseudogenes are common and are encountered in a diverse
range of life forms, but particularly vertebrates. Genome com-
plexity has evolved by the generation of gene families via gene
duplication, but for reasons that remain contentious, some of
these duplicated genes have become non-functional pseudo-
genes. Retrotransposed pseudogenes arise by a completely
di¡erent mechanism and re£ect a di¡erent aspect of genome
evolution. Once established within a genome, pseudogenes
evolve with time, although the mechanisms that control these
changes remain very poorly understood.
Most pseudogenes have multiple features that con¢rm their
non-functional status. However, there are genes that have
many features of pseudogenes, but which are functional,
and a separate group of genes that are currently considered
as pseudogenes, but with the recognition that these genes are
potentially functional. Accordingly, experimental design and
interpretation across the whole ¢eld of molecular genetics
must take pseudogenes into careful consideration.
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